Company Encyclopedia
View More
name
ZZYL
600568.SH
Zhongzhu Healthcare Holding Co.,Ltd engages in the research and development, production, and sale of drugs in China. The company offers ophthalmology drugs, including Pearl eye drops, Sodium Cromolyn eye drops, Acyclovir eye drops, Hydroxybenzone Hydrochloride eye drops, Acyclovir dispersible tablets, and Gatifloxacin tablets; and products related to tumor treatment. It is also involved in production and sales of products of hepatest ultrasonic liver cirrhosis detector, infusion heater, and Moon God whole body gamma knife. In addition, the company develops 1.1-class chemical drug Leonurine (SCM-198) project with the effect of lowering blood lipids and preventing and treating stroke; and genistein capsules for the treatment of osteoporosis.
902.18 B
600568.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Real Estate DevelopmentIndustry
Industry Ranking48/81
Industry medianD
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-28.13%E
    • Profit Margin-98.42%E
    • Gross Margin21.74%D
  • Growth ScoreE
    • Revenue YoY-11.06%E
    • Net Profit YoY-212.60%E
    • Total Assets YoY-22.01%E
    • Net Assets YoY-24.76%E
  • Cash ScoreD
    • Cash Flow Margin-101.61%D
    • OCF YoY-11.06%E
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreA
    • Gearing Ratio17.18%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST ZZYL: Net loss of 24.1372 million yuan in the first half of 2025, a year-on-year narrowing of 63.04%

    ST ZZYL announced that in the first half of 2025, the operating revenue was 303 million yuan, a year-on-year increase of 20.29%. The net loss attributable to shareholders of the listed company was 24.1372 million yuan, a year-on-year narrowing of 63.04%. The basic earnings per share were -0.0122 yuan/share, a year-on-year increase of 63.03%

    Zhitong·
    SH
    600568
    -3.72%
    Zhitong·
    SH
    600568
    -3.72%

    ST ZZYL: Appointed Liu Huiping as the company's vice president

    On August 15th, ST ZZYL announced that the eighth meeting of the tenth board of directors approved the appointment of Liu Huiping as the company's vice president, with a term starting from the date of approval by the tenth board of directors until the completion of the re-election of the tenth board of directors

    Zhitong·
    SH
    600568
    -3.72%
    Zhitong·
    SH
    600568
    -3.72%

    The medical information sector weakened, and ST ZZYL hit the limit down

    36Kr learned that as of the time of publication, the medical information sector weakened, with ST ZZYL hitting the limit down, and Yonyou, Qi An Xin-U, Hongjing Technology, Runda Medical, SunwayWorld, and Weining Health also following the decline

    36Kr·
    SH
    603108
    +1.42%
    SH
    600568
    -3.72%
    SZ
    301159
    +2.69%
    36Kr·
    SH
    603108
    +1.42%
    SH
    600568
    -3.72%
    SZ
    301159
    +2.69%

    ZZYL: Net loss of 17.7799 million yuan in the first quarter of 2025

    ST ZZYL announced that its revenue for the first quarter of 2025 was 141 million yuan, a year-on-year increase of 8.81%; the net loss was 17.7799 million yuan, compared to a net loss of 22.8936 million yuan in the same period last year

    Zhitong·
    SH
    600568
    -3.72%
    Zhitong·
    SH
    600568
    -3.72%

    ST ZZYL released its 2024 annual performance, with a net loss attributable to the parent company of 620 million yuan, an expanded loss

    According to the Zhitong Finance APP, ST ZZYL released its 2024 annual report, stating that the company's operating revenue for 2024 is 521 million yuan, a year-on-year decrease of 18.35%; the net loss attributable to shareholders of the listed company is 620 million yuan, with losses widening; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses is 624 million yuan, with losses widening; the basic loss per share is 0.3148 yuan/share

    Zhitong·
    SH
    600568
    -3.72%
    Zhitong·
    SH
    600568
    -3.72%
    © 2025 Longbridge｜Disclaimer